Amanote Research
Register
Sign In
Pirfenidone Should Be Prescribed for Patients With Idiopathic Pulmonary Fibrosis: Table 1
Thorax
- United Kingdom
doi 10.1136/thoraxjnl-2011-201268
Full Text
Open PDF
Abstract
Available in
full text
Categories
Pulmonary
Respiratory Medicine
Date
March 5, 2013
Authors
Gisli Jenkins
Publisher
BMJ
Related search
Idiopathic Pulmonary Fibrosis and Pirfenidone
European Respiratory Journal
Medicine
Pulmonary
Respiratory Medicine
Efficacy of Pirfenidone in Patients With Advanced-Stage Idiopathic Pulmonary Fibrosis
Internal Medicine
Internal Medicine
Medicine
Effect of Perioperative Pirfenidone Treatment in Lung Cancer Patients With Idiopathic Pulmonary Fibrosis
Annals of Thoracic Surgery
Respiratory Medicine
Pulmonary
Cardiovascular Medicine
Surgery
Cardiology
Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis and More Advanced Lung Function Impairment
Respiratory Medicine
Pulmonary
Respiratory Medicine
Pirfenidone Treatment in Idiopathic Pulmonary Fibrosis: Nationwide Danish Results
European Clinical Respiratory Journal
P196 Healthcare Utilisation by Patients With Idiopathic Pulmonary Fibrosis; Observations From the UK Pirfenidone Named Patient Programme
Thorax
Pulmonary
Respiratory Medicine
Prs41 - Cost-Effectiveness of Pirfenidone for the Treatment of Patients With Mild to Moderate Idiopathic Pulmonary Fibrosis in Greece
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Analysis of Patients With Idiopathic Pulmonary Fibrosis (IPF) With More Severe Lung Function Impairment Treated With Pirfenidone in Recap
Chest
Cardiology
Critical Care
Cardiovascular Medicine
Intensive Care Medicine
Pulmonary
Respiratory Medicine
Evaluating the Annual Cost Per Response Rate of Pirfenidone and Nintedanib for the Treatment of Patients With Idiopathic Pulmonary Fibrosis
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
